Galapagos NV ((GLPG)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Galapagos NV is conducting a study titled ‘A Phase I/II, Multicenter Study Evaluating the Feasibility, Safety, and Efficacy of Point-of-care Manufactured GLPG5101 (19CP02) in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to determine if GLPG5101 is effective and safe for treating non-Hodgkin lymphoma, focusing on dose optimization and expansion to assess efficacy.
Intervention/Treatment: The study tests GLPG5101, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, designed to target and treat B-cell non-Hodgkin lymphoma.
Study Design: This interventional study is non-randomized with a sequential intervention model. It involves no masking and primarily aims to treat the condition by determining the optimal dose in Phase I and expanding to various cohorts in Phase II.
Study Timeline: The study began on August 16, 2024, with the latest update submitted on August 26, 2025. These dates are crucial for tracking progress and ensuring timely updates on the study’s recruitment and results.
Market Implications: The progress of this study could significantly impact Galapagos NV’s stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the oncology market. The ongoing development of GLPG5101 could represent a breakthrough in CAR T cell therapies, potentially influencing industry trends.
The study is currently recruiting, with further details available on the ClinicalTrials portal.